Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic treatments for rare bleeding and thrombotic disorders, has raised $157 million in a heavily oversubscribed Series C financing round.
The round was led by Sofinnova Partners with significant participation from a major global asset management firm, a sovereign wealth fund, Avoro Capital Advisors, and existing investors including RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital. As part of the financing, Joe Anderson, PhD, Partner at Sofinnova Partners, will join Hemab’s Board of Directors.
The new funding will support the advancement of Hemab’s pipeline, including sutacimig, the first-ever prophylactic treatment for Glanzmann thrombasthenia (GT), a rare and potentially life-threatening bleeding disorder. Following successful completion of a Phase 2 study in GT, Hemab plans to begin a registration study in 2026 and initiate a Phase 2 study in Factor VII deficiency.
Hemab is also advancing HMB-002, an antibody-based therapy for Von Willebrand disease (VWD). Phase 1 data have shown that it directly targets the underlying cause of the disease by increasing Von Willebrand Factor and Factor VIII levels. A registration study for HMB-002 is expected to follow, offering new hope for VWD patients who have long lacked prophylactic treatment options.
Patient advocates have voiced strong support for Hemab’s work. “We feel so limited by the lack of effective treatments in emergencies and cannot stress enough how urgently we need breakthrough therapies,” said Alexandra Sullivan, a mother of two children with GT. Similarly, Jeanette Cesta, Executive Director of the VWD Connect Foundation, said HMB-002 represents “the kind of innovative, patient-centered treatment our community has been waiting for.”
Hemab’s development programs have been guided by extensive natural history studies—GT360, FVIID360, and VWD360—that have revealed the broader burden of these diseases, including chronic pain, immobility, and emotional challenges. The company plans to expand its pipeline further, with a new candidate, HMB-003, expected to enter clinical development in the first half of 2026.
“The quality of our investor syndicate and this significant financing validate our approach,” said Benny Sorensen, MD, PhD, CEO of Hemab. “This funding accelerates our mission of transforming lives for people who have waited far too long for modern treatments.”
Sofinnova’s Joe Anderson added, “Hemab’s focus on patients and its scientific excellence make it a standout in the biotech landscape. We’re excited to support their mission to bring transformative therapies to underserved patient populations.”